Acasti has an exclusive licence from Neptune to develop pharmaceutical products customized to manage cardiovascular disease. CaPre® is currently Acasti’s only prescription drug candidate, and is being developed to address the prevention and treatment of cardiometabolic disorders including hypertriglyceridemia, a condition which is characterized by abnormally high levels of triglycerides.
CaPre® is composed of a patent-protected highly concentrated novel omega-3 phospholipid derived from krill oil for the prevention and treatment of certain cardiometabolic disorders. The active ingredient of CaPre® is a mixture of concentrated omega-3 fatty acids purified from krill oil and developed as an oral formulation. CaPre® contains EPA and DHA bound to phospholipids as well as free EPA and DHA.
Acasti’s near-term strategy is to develop and commercialize CaPre® in the United States as a prescription drug with a claim for the treatment of severe hypertriglyceridemia and, as a next step, the treatment of mild to moderate hypertriglyceridemia.
Going forward Acasti hopes, CaPre® can be used as a therapy in conjunction with positive lifestyle changes and administered either alone or with other treatments such as statins (statins are a class of drug used to reduce cholesterol levels) and potentially for use by statin-intolerant or statin-resistant patients.